Trial Outcomes & Findings for Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis (NCT NCT01480076)

NCT ID: NCT01480076

Last Updated: 2017-03-21

Results Overview

The SF-36 determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 primarily contribute to the PCS score of the SF-36. Items 5-8 primarily contribute to the mental component summary (MCS) score of the SF-36. Scores on each item are summed and averaged (range: 0=worst to 100=best). Increases from baseline indicate improvement. Within-group least squares means are presented.

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

901 participants

Primary outcome timeframe

Baseline, Months 3, 6, 9, 12

Results posted on

2017-03-21

Participant Flow

Participant milestones

Participant milestones
Measure
Fampridine
All participants took 10 mg fampridine twice daily for the first 4 weeks. If deemed a treatment responder, the participant continued 10 mg fampridine twice daily for 44 weeks. Treatment non-responders continued without treatment by completing quality of life questionnaires.
Overall Study
STARTED
901
Overall Study
Intent to Treat Population
835
Overall Study
COMPLETED
611
Overall Study
NOT COMPLETED
290

Reasons for withdrawal

Reasons for withdrawal
Measure
Fampridine
All participants took 10 mg fampridine twice daily for the first 4 weeks. If deemed a treatment responder, the participant continued 10 mg fampridine twice daily for 44 weeks. Treatment non-responders continued without treatment by completing quality of life questionnaires.
Overall Study
Run-in Failure
52
Overall Study
Adverse Event
39
Overall Study
Death
2
Overall Study
Disease Progression
5
Overall Study
Non-compliance With Study Protocol
15
Overall Study
Withdrawal by Subject
105
Overall Study
Lost to Follow-up
7
Overall Study
Investigator Decision
13
Overall Study
Other
52

Baseline Characteristics

Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Responder
n=707 Participants
Participants took 10 mg fampridine twice daily for the first 4 weeks. If deemed a treatment responder, the participant continued 10 mg fampridine twice daily for 44 weeks.
Non-responder
n=128 Participants
Participants took 10 mg fampridine twice daily for the first 4 weeks. Treatment non-responders continued without treatment by completing quality of life questionnaires.
Total
n=835 Participants
Total of all reporting groups
Age, Continuous
49.3 years
STANDARD_DEVIATION 9.70 • n=99 Participants
50.5 years
STANDARD_DEVIATION 10.0 • n=107 Participants
49.5 years
STANDARD_DEVIATION 9.75 • n=206 Participants
Sex: Female, Male
Female
402 Participants
n=99 Participants
79 Participants
n=107 Participants
481 Participants
n=206 Participants
Sex: Female, Male
Male
305 Participants
n=99 Participants
49 Participants
n=107 Participants
354 Participants
n=206 Participants

PRIMARY outcome

Timeframe: Baseline, Months 3, 6, 9, 12

Population: Participants in the intent-to-treat population (all participants who received at least 1 dose of study treatment and who provided at least 1 efficacy assessment at Baseline and the 3-month visit) who were included in the mixed effect model for repeated measures analysis.

The SF-36 determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 primarily contribute to the PCS score of the SF-36. Items 5-8 primarily contribute to the mental component summary (MCS) score of the SF-36. Scores on each item are summed and averaged (range: 0=worst to 100=best). Increases from baseline indicate improvement. Within-group least squares means are presented.

Outcome measures

Outcome measures
Measure
Secondary-Progressive MS
Participants in the Responder group with secondary-progressive MS (SPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Primary-Progressive MS
Participants in the Responder group with primary-progressive MS (PPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Progressive-Relapsing MS
Participants in the Responder group with progressive-relapsing MS (PRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Relapsing-Remitting MS
n=666 Participants
Participants in the Responder group with relapsing-remitting MS (RRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Change From Baseline in the Physical Component Scale (PCS) of the Short Form 36 Health Status Questionnaire (SF-36) At Months 3, 6, 9, and 12: Responders
Month 3
4.2 units on a scale
Standard Error 0.36
Change From Baseline in the Physical Component Scale (PCS) of the Short Form 36 Health Status Questionnaire (SF-36) At Months 3, 6, 9, and 12: Responders
Month 6
3.4 units on a scale
Standard Error 0.38
Change From Baseline in the Physical Component Scale (PCS) of the Short Form 36 Health Status Questionnaire (SF-36) At Months 3, 6, 9, and 12: Responders
Month 9
3.2 units on a scale
Standard Error 0.37
Change From Baseline in the Physical Component Scale (PCS) of the Short Form 36 Health Status Questionnaire (SF-36) At Months 3, 6, 9, and 12: Responders
Month 12
2.9 units on a scale
Standard Error 0.37

SECONDARY outcome

Timeframe: Baseline, Months 3, 6, 9, 12

Population: Participants in the intent-to-treat population (all participants who received at least 1 dose of study treatment and who provided at least 1 efficacy assessment at Baseline and the 3-month visit) who were included in the mixed effect model for repeated measures analysis.

The SF-36 determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 primarily contribute to the PCS score of the SF-36. Items 5-8 primarily contribute to the MCS score of the SF-36. Scores on each item are summed and averaged (range: 0=worst to 100=best). Increases from baseline indicate improvement. The 'overall' estimate is the average change from baseline over the whole time period (through Month 12). In contrast to the primary endpoint, this analysis was done using data from both responder and non-responder groups; therefore, 'responder group' and 'visit by responder group interaction' were included as fixed effects.

Outcome measures

Outcome measures
Measure
Secondary-Progressive MS
n=81 Participants
Participants in the Responder group with secondary-progressive MS (SPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Primary-Progressive MS
Participants in the Responder group with primary-progressive MS (PPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Progressive-Relapsing MS
Participants in the Responder group with progressive-relapsing MS (PRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Relapsing-Remitting MS
n=666 Participants
Participants in the Responder group with relapsing-remitting MS (RRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Change From Baseline in the PCS of the SF-36 at Months 3, 6, 9, and 12: Responders Versus Non-responders
Overall
-0.4 units on a scale
Standard Error 0.63
3.3 units on a scale
Standard Error 0.34
Change From Baseline in the PCS of the SF-36 at Months 3, 6, 9, and 12: Responders Versus Non-responders
Month 3
-0.2 units on a scale
Standard Error 0.67
4.0 units on a scale
Standard Error 0.36
Change From Baseline in the PCS of the SF-36 at Months 3, 6, 9, and 12: Responders Versus Non-responders
Month 6
0.2 units on a scale
Standard Error 0.77
3.3 units on a scale
Standard Error 0.37
Change From Baseline in the PCS of the SF-36 at Months 3, 6, 9, and 12: Responders Versus Non-responders
Month 9
-1.1 units on a scale
Standard Error 0.80
3.0 units on a scale
Standard Error 0.37
Change From Baseline in the PCS of the SF-36 at Months 3, 6, 9, and 12: Responders Versus Non-responders
Month 12
-0.5 units on a scale
Standard Error 0.81
2.8 units on a scale
Standard Error 0.37

SECONDARY outcome

Timeframe: Baseline, Months 3, 6, 9, 12

Population: Participants in the intent-to-treat population (all participants who received at least 1 dose of study treatment and who provided at least 1 efficacy assessment at Baseline and the 3-month visit) who were included in the mixed effect model for repeated measures analysis.

The SF-36 determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 primarily contribute to the PCS score of the SF-36. Items 5-8 primarily contribute to the MCS score of the SF-36. Scores on each item are summed and averaged (range: 0=worst to 100=best). Increases from baseline indicate improvement. The 'overall' estimate is the average change from baseline over the whole time period (through Month 12).

Outcome measures

Outcome measures
Measure
Secondary-Progressive MS
n=81 Participants
Participants in the Responder group with secondary-progressive MS (SPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Primary-Progressive MS
Participants in the Responder group with primary-progressive MS (PPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Progressive-Relapsing MS
Participants in the Responder group with progressive-relapsing MS (PRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Relapsing-Remitting MS
n=667 Participants
Participants in the Responder group with relapsing-remitting MS (RRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Change From Baseline in the MCS of the SF-36 At Months 3, 6, 9, and 12
Month 12
-0.6 units on a scale
Standard Error 1.21
2.5 units on a scale
Standard Error 0.57
Change From Baseline in the MCS of the SF-36 At Months 3, 6, 9, and 12
Overall
0.1 units on a scale
Standard Error 0.95
3.1 units on a scale
Standard Error 0.53
Change From Baseline in the MCS of the SF-36 At Months 3, 6, 9, and 12
Month 3
-0.6 units on a scale
Standard Error 1.03
4.2 units on a scale
Standard Error 0.55
Change From Baseline in the MCS of the SF-36 At Months 3, 6, 9, and 12
Month 6
0.6 units on a scale
Standard Error 1.12
3.3 units on a scale
Standard Error 0.56
Change From Baseline in the MCS of the SF-36 At Months 3, 6, 9, and 12
Month 9
1.0 units on a scale
Standard Error 1.22
2.3 units on a scale
Standard Error 0.58

SECONDARY outcome

Timeframe: Baseline, Months 3, 6, 9, 12

Population: Participants in the intent-to-treat population (all participants who received at least 1 dose of study treatment and who provided at least 1 efficacy assessment at Baseline and the 3-month visit) who were included in the mixed effect model for repeated measures analysis.

The MSIS-29 is a disease specific patient-reported outcome measure that has been developed and validated to examine the physical and psychological impact of MS from a patient's perspective; it measures 20 physical items and 9 psychological items. Sum of 20 physical condition items converted into a 0-100 score range, where missing items are imputed by average of total of non-missing items when no more than 50% are missing (otherwise the total score is missing). A lower total score indicates less physically-related impact while a higher total score indicates greater physically-related impact on a participant's functioning. Decreases from Baseline indicate improvement. A mixed effect model for repeated measures was used for this analysis. An unstructured covariance was used to model within-participant error. The 'overall' estimate is the average change from baseline over the whole time period (through Month 12).

Outcome measures

Outcome measures
Measure
Secondary-Progressive MS
n=79 Participants
Participants in the Responder group with secondary-progressive MS (SPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Primary-Progressive MS
Participants in the Responder group with primary-progressive MS (PPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Progressive-Relapsing MS
Participants in the Responder group with progressive-relapsing MS (PRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Relapsing-Remitting MS
n=669 Participants
Participants in the Responder group with relapsing-remitting MS (RRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Change From Baseline in the Multiple Sclerosis Impact Scale (MSIS-29) Physical Score at Months 3, 6, 9, and 12
Overall
-2.1 units on a scale
Standard Error 1.79
-10.3 units on a scale
Standard Error 0.99
Change From Baseline in the Multiple Sclerosis Impact Scale (MSIS-29) Physical Score at Months 3, 6, 9, and 12
Month 3
-2.1 units on a scale
Standard Error 1.83
-13.0 units on a scale
Standard Error 1.00
Change From Baseline in the Multiple Sclerosis Impact Scale (MSIS-29) Physical Score at Months 3, 6, 9, and 12
Month 6
-3.0 units on a scale
Standard Error 1.99
-10.6 units on a scale
Standard Error 1.03
Change From Baseline in the Multiple Sclerosis Impact Scale (MSIS-29) Physical Score at Months 3, 6, 9, and 12
Month 9
-0.3 units on a scale
Standard Error 2.19
-8.9 units on a scale
Standard Error 1.06
Change From Baseline in the Multiple Sclerosis Impact Scale (MSIS-29) Physical Score at Months 3, 6, 9, and 12
Month 12
-2.8 units on a scale
Standard Error 2.23
-8.6 units on a scale
Standard Error 1.06

SECONDARY outcome

Timeframe: Baseline, Months 3, 6, 9, 12

Population: Participants in the intent-to-treat population (all participants who received at least 1 dose of study treatment and who provided at least 1 efficacy assessment at Baseline and the 3-month visit) who were included in the mixed effect model for repeated measures analysis.

The MSIS-29 is a disease specific patient-reported outcome measure that has been developed and validated to examine the physical and psychological impact of MS from a patient's perspective; it measures 20 physical items and 9 psychological items. Sum of 9 psychological condition items converted into a 0-100 score range, where missing items are imputed by average of total of non-missing items when no more than 50% are missing (otherwise the total score is missing). A lower total score indicates less psychologically-related impact while a higher total score indicates greater psychologically-related impact on a participant's functioning. Decreases from Baseline indicate improvement. A mixed effect model for repeated measures was used for this analysis. An unstructured covariance was used to model within-participant error. The 'overall' estimate is the average change from baseline over the whole time period (through Month 12).

Outcome measures

Outcome measures
Measure
Secondary-Progressive MS
n=79 Participants
Participants in the Responder group with secondary-progressive MS (SPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Primary-Progressive MS
Participants in the Responder group with primary-progressive MS (PPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Progressive-Relapsing MS
Participants in the Responder group with progressive-relapsing MS (PRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Relapsing-Remitting MS
n=669 Participants
Participants in the Responder group with relapsing-remitting MS (RRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Change From Baseline in MSIS-29 Psychological Score at Months 3, 6, 9, and 12
Overall
-1.0 units on a scale
Standard Error 1.77
-7.8 units on a scale
Standard Error 0.97
Change From Baseline in MSIS-29 Psychological Score at Months 3, 6, 9, and 12
Month 3
-0.2 units on a scale
Standard Error 1.91
-9.6 units on a scale
Standard Error 1.01
Change From Baseline in MSIS-29 Psychological Score at Months 3, 6, 9, and 12
Month 6
-2.6 units on a scale
Standard Error 2.06
-7.7 units on a scale
Standard Error 1.03
Change From Baseline in MSIS-29 Psychological Score at Months 3, 6, 9, and 12
Month 9
-0.8 units on a scale
Standard Error 2.26
-6.8 units on a scale
Standard Error 1.06
Change From Baseline in MSIS-29 Psychological Score at Months 3, 6, 9, and 12
Month 12
-0.5 units on a scale
Standard Error 2.34
-7.0 units on a scale
Standard Error 1.06

SECONDARY outcome

Timeframe: Baseline, Months 3, 6, 9, 12

Population: Participants in the intent-to-treat population (all participants who received at least 1 dose of study treatment and who provided at least 1 efficacy assessment at Baseline and the 3-month visit) who were included in the mixed effect model for repeated measures analysis.

The PRIMUS activity measure is a 15-item assessment of patient-reported activities of daily living. The total score was calculated as sum of all 15 items converted into a 0-30 range, where missing items were imputed by average of non-missing total when no more than 50% of items were missing (otherwise, the total score is missing). Higher score indicates worse condition. A decrease from Baseline indicates improvement. A mixed effect model for repeated measures was used for this analysis. An unstructured covariance was used to model within-participant error. The 'overall' estimate is the average change from baseline over the whole time period (through Month 12).

Outcome measures

Outcome measures
Measure
Secondary-Progressive MS
n=45 Participants
Participants in the Responder group with secondary-progressive MS (SPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Primary-Progressive MS
Participants in the Responder group with primary-progressive MS (PPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Progressive-Relapsing MS
Participants in the Responder group with progressive-relapsing MS (PRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Relapsing-Remitting MS
n=498 Participants
Participants in the Responder group with relapsing-remitting MS (RRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Change From Baseline in the Activities Limitation Scale of the Patient-Reported Indices for Multiple Sclerosis (PRIMUS) at Months 3, 6, 9, and 12
Overall
0.8 units on a scale
Standard Error 0.56
-1.4 units on a scale
Standard Error 0.22
Change From Baseline in the Activities Limitation Scale of the Patient-Reported Indices for Multiple Sclerosis (PRIMUS) at Months 3, 6, 9, and 12
Month 3
-0.4 units on a scale
Standard Error 0.58
-2.3 units on a scale
Standard Error 0.23
Change From Baseline in the Activities Limitation Scale of the Patient-Reported Indices for Multiple Sclerosis (PRIMUS) at Months 3, 6, 9, and 12
Month 6
0.8 units on a scale
Standard Error 0.70
-1.4 units on a scale
Standard Error 0.25
Change From Baseline in the Activities Limitation Scale of the Patient-Reported Indices for Multiple Sclerosis (PRIMUS) at Months 3, 6, 9, and 12
Month 9
1.8 units on a scale
Standard Error 0.73
-1.2 units on a scale
Standard Error 0.25
Change From Baseline in the Activities Limitation Scale of the Patient-Reported Indices for Multiple Sclerosis (PRIMUS) at Months 3, 6, 9, and 12
Month 12
1.1 units on a scale
Standard Error 0.83
-0.8 units on a scale
Standard Error 0.26

SECONDARY outcome

Timeframe: Baseline, Months 3, 6, 9, 12

Population: Participants in the intent-to-treat population (all participants who received at least 1 dose of study treatment and who provided at least 1 efficacy assessment at Baseline and the 3-month visit) who were included in the mixed effect model for repeated measures analysis.

EQ-5D is a participant-answered questionnaire containing a descriptive system of 5 dimensions - mobility, self-care, usual activities, pain/discomfort and anxiety/depression and a VAS on health state. The EQ-5D VAS ranges from 0 (worst health state) to 100 (best health state). An increase from baseline indicates improvement. A mixed effect model for repeated measures was used for this analysis. An unstructured covariance was used to model within-participant error. The 'overall' estimate is the average change from baseline over the whole time period (through Month 12).

Outcome measures

Outcome measures
Measure
Secondary-Progressive MS
n=79 Participants
Participants in the Responder group with secondary-progressive MS (SPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Primary-Progressive MS
Participants in the Responder group with primary-progressive MS (PPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Progressive-Relapsing MS
Participants in the Responder group with progressive-relapsing MS (PRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Relapsing-Remitting MS
n=659 Participants
Participants in the Responder group with relapsing-remitting MS (RRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Change From Baseline in the Current Health State of EuroQoL Descriptive System of Health-related Quality of Life States Consisting of 5 Dimensions (EQ-5D) Visual Analog Scale (VAS) at Months 3, 6, 9, And 12
Overall
-4.4 units on a scale
Standard Error 1.73
6.7 units on a scale
Standard Error 0.95
Change From Baseline in the Current Health State of EuroQoL Descriptive System of Health-related Quality of Life States Consisting of 5 Dimensions (EQ-5D) Visual Analog Scale (VAS) at Months 3, 6, 9, And 12
Month 3
-3.2 units on a scale
Standard Error 1.91
8.0 units on a scale
Standard Error 1.00
Change From Baseline in the Current Health State of EuroQoL Descriptive System of Health-related Quality of Life States Consisting of 5 Dimensions (EQ-5D) Visual Analog Scale (VAS) at Months 3, 6, 9, And 12
Month 6
-3.6 units on a scale
Standard Error 2.06
6.1 units on a scale
Standard Error 1.02
Change From Baseline in the Current Health State of EuroQoL Descriptive System of Health-related Quality of Life States Consisting of 5 Dimensions (EQ-5D) Visual Analog Scale (VAS) at Months 3, 6, 9, And 12
Month 9
-4.9 units on a scale
Standard Error 2.21
6.3 units on a scale
Standard Error 1.04
Change From Baseline in the Current Health State of EuroQoL Descriptive System of Health-related Quality of Life States Consisting of 5 Dimensions (EQ-5D) Visual Analog Scale (VAS) at Months 3, 6, 9, And 12
Month 12
-6.0 units on a scale
Standard Error 2.34
6.3 units on a scale
Standard Error 1.05

SECONDARY outcome

Timeframe: Baseline, Months 3, 6, 9, 12

Population: Participants in the intent-to-treat population (all participants who received at least 1 dose of study treatment and who provided at least 1 efficacy assessment at Baseline and the 3-month visit) who were included in the mixed effect model for repeated measures analysis.

EQ-5D is a participant-answered questionnaire containing a descriptive system on 5 dimensions - mobility, self-care, usual activities, pain/discomfort and anxiety/depression and a VAS on health state. The scores on the 5 dimensions of descriptive system can be converted into an index score by applying United Kingdom (UK) weights. EQ-5D index score ranges from 1 to -0.59, and 1 reflects the best outcome. An increase from baseline indicates improvement. A mixed effect model for repeated measures was used for this analysis. An unstructured covariance was used to model within-participant error. The 'overall' estimate is the average change from baseline over the whole time period (through Month 12).

Outcome measures

Outcome measures
Measure
Secondary-Progressive MS
n=78 Participants
Participants in the Responder group with secondary-progressive MS (SPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Primary-Progressive MS
Participants in the Responder group with primary-progressive MS (PPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Progressive-Relapsing MS
Participants in the Responder group with progressive-relapsing MS (PRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Relapsing-Remitting MS
n=661 Participants
Participants in the Responder group with relapsing-remitting MS (RRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Change From Baseline in the Index Scores of EQ-5D at Months 3, 6, 9, and 12
Overall
0.00 units on a scale
Standard Error 0.02
0.05 units on a scale
Standard Error 0.01
Change From Baseline in the Index Scores of EQ-5D at Months 3, 6, 9, and 12
Month 3
0.01 units on a scale
Standard Error 0.02
0.07 units on a scale
Standard Error 0.01
Change From Baseline in the Index Scores of EQ-5D at Months 3, 6, 9, and 12
Month 6
0.01 units on a scale
Standard Error 0.02
0.05 units on a scale
Standard Error 0.01
Change From Baseline in the Index Scores of EQ-5D at Months 3, 6, 9, and 12
Month 9
0.01 units on a scale
Standard Error 0.03
0.04 units on a scale
Standard Error 0.01
Change From Baseline in the Index Scores of EQ-5D at Months 3, 6, 9, and 12
Month 12
-0.01 units on a scale
Standard Error 0.03
0.04 units on a scale
Standard Error 0.01

SECONDARY outcome

Timeframe: Baseline, Months 3, 6, 9, 12

Population: Participants in the intent-to-treat population (all participants who received at least 1 dose of study treatment and who provided at least 1 efficacy assessment at Baseline and the 3-month visit) who were included in the mixed effect model for repeated measures analysis.

WPAI-SHP is a 6-question participant-rated questionnaire to determine degree to which a specific health problem affected work productivity while at work and outside of work. Four scores are derived: percentage of absenteeism (percentage of work time missed) and presenteeism (reduced productivity while at work), overall work impairment score combining absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. Score range: 0 (not affected/no impairment) to 100 (completely affected/impaired). WPAI outcomes are expressed as impairment percentages with higher numbers indicating greater impairment and less productivity. A decrease from Baseline indicates improvement. A mixed effect model for repeated measures was used for this analysis. An unstructured covariance was used to model within-participant error. The 'overall' estimate is the average change from baseline over the whole time period (through Month 12).

Outcome measures

Outcome measures
Measure
Secondary-Progressive MS
n=14 Participants
Participants in the Responder group with secondary-progressive MS (SPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Primary-Progressive MS
Participants in the Responder group with primary-progressive MS (PPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Progressive-Relapsing MS
Participants in the Responder group with progressive-relapsing MS (PRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Relapsing-Remitting MS
n=191 Participants
Participants in the Responder group with relapsing-remitting MS (RRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Change From Baseline in Percent Work Time Missed Due to MS, by the Work Productivity and Activity Impairment-Specific Health Problem (WPAI-SHP) Questionnaire at Months 3, 6, 9, and 12
Overall
-8.3 percentage of work time missed
Standard Error 4.60
-2.5 percentage of work time missed
Standard Error 1.87
Change From Baseline in Percent Work Time Missed Due to MS, by the Work Productivity and Activity Impairment-Specific Health Problem (WPAI-SHP) Questionnaire at Months 3, 6, 9, and 12
Month 3
-4.0 percentage of work time missed
Standard Error 5.81
-3.0 percentage of work time missed
Standard Error 2.15
Change From Baseline in Percent Work Time Missed Due to MS, by the Work Productivity and Activity Impairment-Specific Health Problem (WPAI-SHP) Questionnaire at Months 3, 6, 9, and 12
Month 6
-7.6 percentage of work time missed
Standard Error 5.07
-5.3 percentage of work time missed
Standard Error 1.95
Change From Baseline in Percent Work Time Missed Due to MS, by the Work Productivity and Activity Impairment-Specific Health Problem (WPAI-SHP) Questionnaire at Months 3, 6, 9, and 12
Month 9
-9.6 percentage of work time missed
Standard Error 7.77
-1.1 percentage of work time missed
Standard Error 2.31
Change From Baseline in Percent Work Time Missed Due to MS, by the Work Productivity and Activity Impairment-Specific Health Problem (WPAI-SHP) Questionnaire at Months 3, 6, 9, and 12
Month 12
-12.1 percentage of work time missed
Standard Error 6.54
-0.7 percentage of work time missed
Standard Error 2.24

SECONDARY outcome

Timeframe: Baseline, Months 3, 6, 9, 12

Population: Participants in the intent-to-treat population (all participants who received at least 1 dose of study treatment and who provided at least 1 efficacy assessment at Baseline and the 3-month visit) who were included in the mixed effect model for repeated measures analysis.

WPAI-SHP is a 6-question participant-rated questionnaire to determine degree to which a specific health problem affected work productivity while at work and outside of work. Four scores are derived: percentage of absenteeism (percentage of work time missed) and presenteeism (reduced productivity while at work), overall work impairment score combining absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. Score range: 0 (not affected/no impairment) to 100 (completely affected/impaired). WPAI outcomes are expressed as impairment percentages with higher numbers indicating greater impairment and less productivity. A decrease from Baseline indicates improvement. A mixed effect model for repeated measures was used for this analysis. An unstructured covariance was used to model within-participant error. The 'overall' estimate is the average change from baseline over the whole time period (through Month 12).

Outcome measures

Outcome measures
Measure
Secondary-Progressive MS
n=16 Participants
Participants in the Responder group with secondary-progressive MS (SPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Primary-Progressive MS
Participants in the Responder group with primary-progressive MS (PPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Progressive-Relapsing MS
Participants in the Responder group with progressive-relapsing MS (PRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Relapsing-Remitting MS
n=217 Participants
Participants in the Responder group with relapsing-remitting MS (RRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Change From Baseline in Percent Impairment While Working Due to MS, by the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12
Overall
-8.4 percentage of impairment while working
Standard Error 4.56
-4.2 percentage of impairment while working
Standard Error 1.88
Change From Baseline in Percent Impairment While Working Due to MS, by the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12
Month 3
-1.8 percentage of impairment while working
Standard Error 5.53
-6.9 percentage of impairment while working
Standard Error 2.09
Change From Baseline in Percent Impairment While Working Due to MS, by the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12
Month 6
-5.6 percentage of impairment while working
Standard Error 5.38
-6.5 percentage of impairment while working
Standard Error 2.01
Change From Baseline in Percent Impairment While Working Due to MS, by the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12
Month 9
-17.9 percentage of impairment while working
Standard Error 6.80
-3.0 percentage of impairment while working
Standard Error 2.18
Change From Baseline in Percent Impairment While Working Due to MS, by the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12
Month 12
-8.4 percentage of impairment while working
Standard Error 6.80
-0.3 percentage of impairment while working
Standard Error 2.22

SECONDARY outcome

Timeframe: Baseline, Months 3, 6, 9, 12

Population: Participants in the intent-to-treat population (all participants who received at least 1 dose of study treatment and who provided at least 1 efficacy assessment at Baseline and the 3-month visit) who were included in the mixed effect model for repeated measures analysis.

WPAI-SHP is a 6-question participant-rated questionnaire to determine degree to which a specific health problem affected work productivity while at work and outside of work. Four scores are derived: percentage of absenteeism (percentage of work time missed) and presenteeism (reduced productivity while at work), overall work impairment score combining absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. Score range: 0 (not affected/no impairment) to 100 (completely affected/impaired). WPAI outcomes are expressed as impairment percentages with higher numbers indicating greater impairment and less productivity. A decrease from Baseline indicates improvement. A mixed effect model for repeated measures was used for this analysis. An unstructured covariance was used to model within-participant error. The 'overall' estimate is the average change from baseline over the whole time period (through Month 12).

Outcome measures

Outcome measures
Measure
Secondary-Progressive MS
n=13 Participants
Participants in the Responder group with secondary-progressive MS (SPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Primary-Progressive MS
Participants in the Responder group with primary-progressive MS (PPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Progressive-Relapsing MS
Participants in the Responder group with progressive-relapsing MS (PRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Relapsing-Remitting MS
n=186 Participants
Participants in the Responder group with relapsing-remitting MS (RRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Change From Baseline in Percent Overall Work Impairment Due to MS, by the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12
Overall
-8.7 percentage of overall work impairment
Standard Error 5.69
-5.2 percentage of overall work impairment
Standard Error 2.24
Change From Baseline in Percent Overall Work Impairment Due to MS, by the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12
Month 3
-4.5 percentage of overall work impairment
Standard Error 6.57
-7.7 percentage of overall work impairment
Standard Error 2.49
Change From Baseline in Percent Overall Work Impairment Due to MS, by the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12
Month 6
-2.9 percentage of overall work impairment
Standard Error 6.73
-7.8 percentage of overall work impairment
Standard Error 2.43
Change From Baseline in Percent Overall Work Impairment Due to MS, by the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12
Month 9
-15.9 percentage of overall work impairment
Standard Error 9.83
-2.4 percentage of overall work impairment
Standard Error 2.86
Change From Baseline in Percent Overall Work Impairment Due to MS, by the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12
Month 12
-11.7 percentage of overall work impairment
Standard Error 7.06
-2.9 percentage of overall work impairment
Standard Error 2.47

SECONDARY outcome

Timeframe: Baseline, Months 3, 6, 9, 12

Population: Participants in the intent-to-treat population (all participants who received at least 1 dose of study treatment and who provided at least 1 efficacy assessment at Baseline and the 3-month visit) who were included in the mixed effect model for repeated measures analysis.

WPAI-SHP is a 6-question participant-rated questionnaire to determine degree to which a specific health problem affected work productivity while at work and outside of work. Four scores are derived: percentage of absenteeism (percentage of work time missed) and presenteeism (reduced productivity while at work), overall work impairment score combining absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. Score range: 0 (not affected/no impairment) to 100 (completely affected/impaired). WPAI outcomes are expressed as impairment percentages with higher numbers indicating greater impairment and less productivity. A decrease from Baseline indicates improvement. A mixed effect model for repeated measures was used for this analysis. An unstructured covariance was used to model within-participant error. The 'overall' estimate is the average change from baseline over the whole time period (through Month 12).

Outcome measures

Outcome measures
Measure
Secondary-Progressive MS
n=77 Participants
Participants in the Responder group with secondary-progressive MS (SPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Primary-Progressive MS
Participants in the Responder group with primary-progressive MS (PPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Progressive-Relapsing MS
Participants in the Responder group with progressive-relapsing MS (PRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Relapsing-Remitting MS
n=650 Participants
Participants in the Responder group with relapsing-remitting MS (RRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Change From Baseline in Regular Activity Productivity Loss, by the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12
Overall
-4.1 percentage of activity impairment
Standard Error 2.37
-11.4 percentage of activity impairment
Standard Error 1.31
Change From Baseline in Regular Activity Productivity Loss, by the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12
Month 3
-3.1 percentage of activity impairment
Standard Error 2.83
-13.5 percentage of activity impairment
Standard Error 1.42
Change From Baseline in Regular Activity Productivity Loss, by the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12
Month 6
-4.7 percentage of activity impairment
Standard Error 2.94
-12.3 percentage of activity impairment
Standard Error 1.43
Change From Baseline in Regular Activity Productivity Loss, by the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12
Month 9
-4.1 percentage of activity impairment
Standard Error 3.08
-10.4 percentage of activity impairment
Standard Error 1.44
Change From Baseline in Regular Activity Productivity Loss, by the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12
Month 12
-4.4 percentage of activity impairment
Standard Error 3.20
-9.2 percentage of activity impairment
Standard Error 1.45

SECONDARY outcome

Timeframe: Baseline, Months 3, 6, 9, and 12

Population: Participants in the intent-to-treat population (all participants who received at least 1 dose of study treatment and who provided at least 1 efficacy assessment at Baseline and the 3-month visit) who were included in the mixed effect model for repeated measures analysis.

The SF-36 determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 primarily contribute to the PCS score of the SF-36. Items 5-8 primarily contribute to the MCS score of the SF-36. Scores on each item are summed and averaged (range: 0=worst to 100=best). Increases from baseline indicate improvement. A mixed effect model for repeated measures was used for this analysis. An unstructured covariance was used to model within-participant error. The 'overall' estimate is the average change from baseline over the whole time period (through Month 12).

Outcome measures

Outcome measures
Measure
Secondary-Progressive MS
n=264 Participants
Participants in the Responder group with secondary-progressive MS (SPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Primary-Progressive MS
n=115 Participants
Participants in the Responder group with primary-progressive MS (PPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Progressive-Relapsing MS
n=31 Participants
Participants in the Responder group with progressive-relapsing MS (PRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Relapsing-Remitting MS
n=256 Participants
Participants in the Responder group with relapsing-remitting MS (RRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Change From Baseline in the PCS of the SF-36 at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Overall
3.8 units on a scale
Standard Error 0.38
2.5 units on a scale
Standard Error 0.49
3.2 units on a scale
Standard Error 0.89
4.5 units on a scale
Standard Error 0.39
Change From Baseline in the PCS of the SF-36 at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Month 3
4.5 units on a scale
Standard Error 0.41
3.1 units on a scale
Standard Error 0.55
2.7 units on a scale
Standard Error 1.01
5.5 units on a scale
Standard Error 0.42
Change From Baseline in the PCS of the SF-36 at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Month 6
3.9 units on a scale
Standard Error 0.45
2.3 units on a scale
Standard Error 0.61
3.9 units on a scale
Standard Error 1.13
4.4 units on a scale
Standard Error 0.46
Change From Baseline in the PCS of the SF-36 at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Month 9
3.2 units on a scale
Standard Error 0.45
3.0 units on a scale
Standard Error 0.60
3.2 units on a scale
Standard Error 1.12
4.2 units on a scale
Standard Error 0.45
Change From Baseline in the PCS of the SF-36 at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Month 12
3.4 units on a scale
Standard Error 0.45
1.7 units on a scale
Standard Error 0.61
2.9 units on a scale
Standard Error 1.14
4.0 units on a scale
Standard Error 0.45

SECONDARY outcome

Timeframe: Baseline, Months 3, 6, 9, and 12

Population: Participants in the intent-to-treat population (all participants who received at least 1 dose of study treatment and who provided at least 1 efficacy assessment at Baseline and the 3-month visit) who were included in the mixed effect model for repeated measures analysis.

The SF-36 determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 primarily contribute to the PCS score of the SF-36. Items 5-8 primarily contribute to the MCS score of the SF-36. Scores on each item are summed and averaged (range: 0=worst to 100=best). Increases from baseline indicate improvement. A mixed effect model for repeated measures was used for this analysis. An unstructured covariance was used to model within-participant error. The 'overall' estimate is the average change from baseline over the whole time period (through Month 12).

Outcome measures

Outcome measures
Measure
Secondary-Progressive MS
n=264 Participants
Participants in the Responder group with secondary-progressive MS (SPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Primary-Progressive MS
n=116 Participants
Participants in the Responder group with primary-progressive MS (PPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Progressive-Relapsing MS
n=31 Participants
Participants in the Responder group with progressive-relapsing MS (PRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Relapsing-Remitting MS
n=256 Participants
Participants in the Responder group with relapsing-remitting MS (RRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Change From Baseline in the MCS of the SF-36 at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Overall
3.0 units on a scale
Standard Error 0.58
3.2 units on a scale
Standard Error 0.74
2.0 units on a scale
Standard Error 1.36
4.0 units on a scale
Standard Error 0.59
Change From Baseline in the MCS of the SF-36 at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Month 3
4.5 units on a scale
Standard Error 0.63
3.9 units on a scale
Standard Error 0.83
2.6 units on a scale
Standard Error 1.54
4.9 units on a scale
Standard Error 0.64
Change From Baseline in the MCS of the SF-36 at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Month 6
2.9 units on a scale
Standard Error 0.66
3.5 units on a scale
Standard Error 0.89
2.9 units on a scale
Standard Error 1.65
4.3 units on a scale
Standard Error 0.67
Change From Baseline in the MCS of the SF-36 at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Month 9
2.1 units on a scale
Standard Error 0.69
2.7 units on a scale
Standard Error 0.93
2.0 units on a scale
Standard Error 1.74
3.1 units on a scale
Standard Error 0.70
Change From Baseline in the MCS of the SF-36 at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Month 12
2.6 units on a scale
Standard Error 0.67
2.5 units on a scale
Standard Error 0.89
0.5 units on a scale
Standard Error 1.68
3.5 units on a scale
Standard Error 0.68

SECONDARY outcome

Timeframe: Baseline, Months 3, 6, 9, and 12

Population: Participants in the intent-to-treat population (all participants who received at least 1 dose of study treatment and who provided at least 1 efficacy assessment at Baseline and the 3-month visit) who were included in the mixed effect model for repeated measures analysis.

The MSIS-29 is a disease-specific patient-reported outcome measure that has been developed and validated to examine the physical and psychological impact of MS from a patient's perspective; it measures 20 physical items and 9 psychological items. Sum of 20 physical condition items converted into a 0-100 score range, where missing items are imputed by average of total of non-missing items when no more than 50% are missing (otherwise the total score is missing). A lower total score indicates less physically-related impact while a higher total score indicates greater physically-related impact on a participant's functioning. Decreases from Baseline indicate improvement. A mixed effect model for repeated measures was used for this analysis. An unstructured covariance was used to model within-participant error. The 'overall' estimate is the average change from baseline over the whole time period (through Month 12).

Outcome measures

Outcome measures
Measure
Secondary-Progressive MS
n=264 Participants
Participants in the Responder group with secondary-progressive MS (SPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Primary-Progressive MS
n=118 Participants
Participants in the Responder group with primary-progressive MS (PPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Progressive-Relapsing MS
n=31 Participants
Participants in the Responder group with progressive-relapsing MS (PRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Relapsing-Remitting MS
n=256 Participants
Participants in the Responder group with relapsing-remitting MS (RRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Change From Baseline in the MSIS-29 Physical Score at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Overall
-10.3 units on a scale
Standard Error 1.09
-8.3 units on a scale
Standard Error 1.40
-12.5 units on a scale
Standard Error 2.58
-12.1 units on a scale
Standard Error 1.12
Change From Baseline in the MSIS-29 Physical Score at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Month 3
-13.3 units on a scale
Standard Error 1.13
-10.6 units on a scale
Standard Error 1.47
-12.6 units on a scale
Standard Error 2.72
-15.0 units on a scale
Standard Error 1.16
Change From Baseline in the MSIS-29 Physical Score at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Month 6
-10.9 units on a scale
Standard Error 1.19
-8.4 units on a scale
Standard Error 1.58
-14.9 units on a scale
Standard Error 2.94
-12.0 units on a scale
Standard Error 1.22
Change From Baseline in the MSIS-29 Physical Score at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Month 9
-8.9 units on a scale
Standard Error 1.25
-7.9 units on a scale
Standard Error 1.67
-10.4 units on a scale
Standard Error 3.13
-10.5 units on a scale
Standard Error 1.27
Change From Baseline in the MSIS-29 Physical Score at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Month 12
-8.2 units on a scale
Standard Error 1.25
-6.2 units on a scale
Standard Error 1.66
-11.9 units on a scale
Standard Error 3.15
-10.9 units on a scale
Standard Error 1.27

SECONDARY outcome

Timeframe: Baseline, Months 3, 6, 9, and 12

Population: Participants in the intent-to-treat population (all participants who received at least 1 dose of study treatment and who provided at least 1 efficacy assessment at Baseline and the 3-month visit) who were included in the mixed effect model for repeated measures analysis.

The MSIS-29 is a disease-specific patient-reported outcome measure that has been developed and validated to examine the physical and psychological impact of MS from a patient's perspective; it measures 20 physical items and 9 psychological items. Sum of 9 psychological condition items converted into a 0-100 score range, where missing items are imputed by average of total of non-missing items when no more than 50% are missing (otherwise the total score is missing). A lower total score indicates less psychologically-related impact while a higher total score indicates greater psychologically-related impact on a participant's functioning. Decreases from Baseline indicate improvement. A mixed effect model for repeated measures was used for this analysis. An unstructured covariance was used to model within-participant error. The 'overall' estimate is the average change from baseline over the whole time period (through Month 12).

Outcome measures

Outcome measures
Measure
Secondary-Progressive MS
n=263 Participants
Participants in the Responder group with secondary-progressive MS (SPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Primary-Progressive MS
n=118 Participants
Participants in the Responder group with primary-progressive MS (PPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Progressive-Relapsing MS
n=31 Participants
Participants in the Responder group with progressive-relapsing MS (PRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Relapsing-Remitting MS
n=257 Participants
Participants in the Responder group with relapsing-remitting MS (RRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Change From Baseline in the MSIS-29 Psychological Score at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Overall
-6.5 units on a scale
Standard Error 1.07
-8.3 units on a scale
Standard Error 1.37
-7.5 units on a scale
Standard Error 2.53
-9.4 units on a scale
Standard Error 1.09
Change From Baseline in the MSIS-29 Psychological Score at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Month 3
-8.9 units on a scale
Standard Error 1.15
-9.1 units on a scale
Standard Error 1.51
-8.6 units on a scale
Standard Error 2.80
-11.2 units on a scale
Standard Error 1.17
Change From Baseline in the MSIS-29 Psychological Score at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Month 6
-6.8 units on a scale
Standard Error 1.22
-8.7 units on a scale
Standard Error 1.62
-7.9 units on a scale
Standard Error 3.06
-8.8 units on a scale
Standard Error 1.23
Change From Baseline in the MSIS-29 Psychological Score at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Month 9
-5.1 units on a scale
Standard Error 1.27
-8.2 units on a scale
Standard Error 1.70
-8.3 units on a scale
Standard Error 3.21
-8.3 units on a scale
Standard Error 1.29
Change From Baseline in the MSIS-29 Psychological Score at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Month 12
-5.3 units on a scale
Standard Error 1.28
-7.4 units on a scale
Standard Error 1.71
-5.1 units on a scale
Standard Error 3.29
-9.3 units on a scale
Standard Error 1.29

SECONDARY outcome

Timeframe: Baseline, Months 3, 6, 9, and 12

Population: Participants in the intent-to-treat population (all participants who received at least 1 dose of study treatment and who provided at least 1 efficacy assessment at Baseline and the 3-month visit) who were included in the mixed effect model for repeated measures analysis.

The PRIMUS activity measure is a 15-item assessment of patient-reported activities of daily living. The total score was calculated as sum of all 15 items converted into a 0-30 range, where missing items were imputed by average of non-missing total when no more than 50% of items were missing (otherwise, the total score is missing). Higher score indicates worse condition. A decrease from Baseline indicates improvement. A mixed effect model for repeated measures was used for this analysis. An unstructured covariance was used to model within-participant error. The 'overall' estimate is the average change from baseline over the whole time period (through Month 12).

Outcome measures

Outcome measures
Measure
Secondary-Progressive MS
n=187 Participants
Participants in the Responder group with secondary-progressive MS (SPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Primary-Progressive MS
n=87 Participants
Participants in the Responder group with primary-progressive MS (PPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Progressive-Relapsing MS
n=26 Participants
Participants in the Responder group with progressive-relapsing MS (PRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Relapsing-Remitting MS
n=198 Participants
Participants in the Responder group with relapsing-remitting MS (RRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Change From Baseline in the Activity Limitation Scale (ALS) of PRIMUS Score at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Overall
-1.1 units on a scale
Standard Error 0.27
-0.5 units on a scale
Standard Error 0.39
-1.7 units on a scale
Standard Error 0.70
-2.5 units on a scale
Standard Error 0.29
Change From Baseline in the Activity Limitation Scale (ALS) of PRIMUS Score at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Month 3
-2.1 units on a scale
Standard Error 0.29
-1.6 units on a scale
Standard Error 0.42
-1.9 units on a scale
Standard Error 0.77
-3.2 units on a scale
Standard Error 0.31
Change From Baseline in the Activity Limitation Scale (ALS) of PRIMUS Score at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Month 6
-1.3 units on a scale
Standard Error 0.34
-0.8 units on a scale
Standard Error 0.48
-1.6 units on a scale
Standard Error 0.88
-2.3 units on a scale
Standard Error 0.35
Change From Baseline in the Activity Limitation Scale (ALS) of PRIMUS Score at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Month 9
-0.7 units on a scale
Standard Error 0.33
-0.3 units on a scale
Standard Error 0.48
-2.0 units on a scale
Standard Error 0.88
-2.4 units on a scale
Standard Error 0.35
Change From Baseline in the Activity Limitation Scale (ALS) of PRIMUS Score at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Month 12
-0.5 units on a scale
Standard Error 0.36
0.7 units on a scale
Standard Error 0.52
-1.2 units on a scale
Standard Error 0.97
-2.0 units on a scale
Standard Error 0.37

SECONDARY outcome

Timeframe: Baseline, Months 3, 6, 9, and 12

Population: Participants in the intent-to-treat population (all participants who received at least 1 dose of study treatment and who provided at least 1 efficacy assessment at Baseline and the 3-month visit) who were included in the mixed effect model for repeated measures analysis.

EQ-5D is a participant-answered questionnaire containing a descriptive system of 5 dimensions - mobility, self-care, usual activities, pain/discomfort and anxiety/depression and a VAS on health state. The EQ-5D VAS ranges from 0 (worst health state) to 100 (best health state). An increase from baseline indicates improvement. A mixed effect model for repeated measures was used for this analysis. An unstructured covariance was used to model within-participant error. The 'overall' estimate is the average change from baseline over the whole time period (through Month 12).

Outcome measures

Outcome measures
Measure
Secondary-Progressive MS
n=258 Participants
Participants in the Responder group with secondary-progressive MS (SPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Primary-Progressive MS
n=116 Participants
Participants in the Responder group with primary-progressive MS (PPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Progressive-Relapsing MS
n=29 Participants
Participants in the Responder group with progressive-relapsing MS (PRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Relapsing-Remitting MS
n=256 Participants
Participants in the Responder group with relapsing-remitting MS (RRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Change From Baseline in Current Health State of the EQ-5D VAS at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Overall
6.5 units on a scale
Standard Error 1.04
6.7 units on a scale
Standard Error 1.34
4.7 units on a scale
Standard Error 2.53
8.8 units on a scale
Standard Error 1.06
Change From Baseline in Current Health State of the EQ-5D VAS at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Month 3
8.2 units on a scale
Standard Error 1.15
7.3 units on a scale
Standard Error 1.53
4.6 units on a scale
Standard Error 2.91
10.1 units on a scale
Standard Error 1.17
Change From Baseline in Current Health State of the EQ-5D VAS at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Month 6
6.1 units on a scale
Standard Error 1.21
6.0 units on a scale
Standard Error 1.63
4.1 units on a scale
Standard Error 3.12
8.0 units on a scale
Standard Error 1.22
Change From Baseline in Current Health State of the EQ-5D VAS at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Month 9
5.6 units on a scale
Standard Error 1.24
7.9 units on a scale
Standard Error 1.66
5.5 units on a scale
Standard Error 3.22
8.2 units on a scale
Standard Error 1.25
Change From Baseline in Current Health State of the EQ-5D VAS at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Month 12
6.1 units on a scale
Standard Error 1.26
5.5 units on a scale
Standard Error 1.70
4.5 units on a scale
Standard Error 3.36
8.8 units on a scale
Standard Error 1.26

SECONDARY outcome

Timeframe: Baseline, Months 3, 6, 9, and 12

Population: Participants in the intent-to-treat population (all participants who received at least 1 dose of study treatment and who provided at least 1 efficacy assessment at Baseline and the 3-month visit) who were included in the mixed effect model for repeated measures analysis.

EQ-5D is a participant-answered questionnaire containing a descriptive system on 5 dimensions - mobility, self-care, usual activities, pain/discomfort and anxiety/depression and a VAS on health state. The scores on the 5 dimensions of descriptive system can be converted into an index score by applying UK weights. EQ-5D index score ranges from 1 to -0.59, and 1 reflects the best outcome. An increase from baseline indicates improvement. A mixed effect model for repeated measures was used for this analysis. An unstructured covariance was used to model within-participant error. The 'overall' estimate is the average change from baseline over the whole time period (through Month 12).

Outcome measures

Outcome measures
Measure
Secondary-Progressive MS
n=262 Participants
Participants in the Responder group with secondary-progressive MS (SPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Primary-Progressive MS
n=114 Participants
Participants in the Responder group with primary-progressive MS (PPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Progressive-Relapsing MS
n=31 Participants
Participants in the Responder group with progressive-relapsing MS (PRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Relapsing-Remitting MS
n=254 Participants
Participants in the Responder group with relapsing-remitting MS (RRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Change From Baseline in EQ-5D Index Scores at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Overall
0.04 units on a scale
Standard Error 0.01
0.05 units on a scale
Standard Error 0.02
0.07 units on a scale
Standard Error 0.03
0.05 units on a scale
Standard Error 0.01
Change From Baseline in EQ-5D Index Scores at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Month 3
0.06 units on a scale
Standard Error 0.01
0.05 units on a scale
Standard Error 0.02
0.06 units on a scale
Standard Error 0.03
0.07 units on a scale
Standard Error 0.01
Change From Baseline in EQ-5D Index Scores at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Month 6
0.05 units on a scale
Standard Error 0.01
0.05 units on a scale
Standard Error 0.02
0.09 units on a scale
Standard Error 0.04
0.04 units on a scale
Standard Error 0.01
Change From Baseline in EQ-5D Index Scores at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Month 9
0.02 units on a scale
Standard Error 0.01
0.04 units on a scale
Standard Error 0.02
0.02 units on a scale
Standard Error 0.04
0.05 units on a scale
Standard Error 0.01
Change From Baseline in EQ-5D Index Scores at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Month 12
0.03 units on a scale
Standard Error 0.01
0.05 units on a scale
Standard Error 0.02
0.10 units on a scale
Standard Error 0.04
0.04 units on a scale
Standard Error 0.01

SECONDARY outcome

Timeframe: Baseline, Months 3, 6, 9, and 12

Population: Participants in the intent-to-treat population (all participants who received at least 1 dose of study treatment and who provided at least 1 efficacy assessment at Baseline and the 3-month visit) who were included in the mixed effect model for repeated measures analysis.

WPAI-SHP is a 6-question participant-rated questionnaire to determine degree to which a specific health problem affected work productivity while at work and outside of work. Four scores are derived: percentage of absenteeism (percentage of work time missed) and presenteeism (reduced productivity while at work), overall work impairment score combining absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. Score range: 0 (not affected/no impairment) to 100 (completely affected/impaired). WPAI outcomes are expressed as impairment percentages with higher numbers indicating greater impairment and less productivity. A decrease from Baseline indicates improvement. A mixed effect model for repeated measures was used for this analysis. An unstructured covariance was used to model within-participant error. The 'overall' estimate is the average change from baseline over the whole time period (through Month 12).

Outcome measures

Outcome measures
Measure
Secondary-Progressive MS
n=55 Participants
Participants in the Responder group with secondary-progressive MS (SPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Primary-Progressive MS
n=34 Participants
Participants in the Responder group with primary-progressive MS (PPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Progressive-Relapsing MS
n=9 Participants
Participants in the Responder group with progressive-relapsing MS (PRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Relapsing-Remitting MS
n=93 Participants
Participants in the Responder group with relapsing-remitting MS (RRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Change From Baseline in Percent Work Time Missed Due to MS on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Overall
-1.5 percentage of work time missed
Standard Error 2.51
-2.5 percentage of work time missed
Standard Error 2.86
-4.0 percentage of work time missed
Standard Error 5.82
-2.9 percentage of work time missed
Standard Error 2.01
Change From Baseline in Percent Work Time Missed Due to MS on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Month 3
-2.6 percentage of work time missed
Standard Error 3.18
-3.3 percentage of work time missed
Standard Error 3.81
-1.1 percentage of work time missed
Standard Error 8.51
-3.1 percentage of work time missed
Standard Error 2.49
Change From Baseline in Percent Work Time Missed Due to MS on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Month 6
-5.3 percentage of work time missed
Standard Error 2.79
-3.3 percentage of work time missed
Standard Error 3.15
-2.3 percentage of work time missed
Standard Error 6.29
-6.4 percentage of work time missed
Standard Error 2.23
Change From Baseline in Percent Work Time Missed Due to MS on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Month 9
2.0 percentage of work time missed
Standard Error 3.68
-1.1 percentage of work time missed
Standard Error 4.44
-10.0 percentage of work time missed
Standard Error 8.77
-1.9 percentage of work time missed
Standard Error 2.86
Change From Baseline in Percent Work Time Missed Due to MS on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Month 12
-0.1 percentage of work time missed
Standard Error 3.44
-2.2 percentage of work time missed
Standard Error 4.12
-2.7 percentage of work time missed
Standard Error 8.24
-0.3 percentage of work time missed
Standard Error 2.67

SECONDARY outcome

Timeframe: Baseline, Months 3, 6, 9, and 12

Population: Participants in the intent-to-treat population (all participants who received at least 1 dose of study treatment and who provided at least 1 efficacy assessment at Baseline and the 3-month visit) who were included in the mixed effect model for repeated measures analysis.

WPAI-SHP is a 6-question participant-rated questionnaire to determine degree to which a specific health problem affected work productivity while at work and outside of work. Four scores are derived: percentage of absenteeism (percentage of work time missed) and presenteeism (reduced productivity while at work), overall work impairment score combining absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. Score range: 0 (not affected/no impairment) to 100 (completely affected/impaired). WPAI outcomes are expressed as impairment percentages with higher numbers indicating greater impairment and less productivity. A decrease from Baseline indicates improvement. A mixed effect model for repeated measures was used for this analysis. An unstructured covariance was used to model within-participant error. The 'overall' estimate is the average change from baseline over the whole time period (through Month 12).

Outcome measures

Outcome measures
Measure
Secondary-Progressive MS
n=62 Participants
Participants in the Responder group with secondary-progressive MS (SPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Primary-Progressive MS
n=40 Participants
Participants in the Responder group with primary-progressive MS (PPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Progressive-Relapsing MS
n=9 Participants
Participants in the Responder group with progressive-relapsing MS (PRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Relapsing-Remitting MS
n=106 Participants
Participants in the Responder group with relapsing-remitting MS (RRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Change From Baseline in Percent Impairment While Working Due to MS on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Overall
-4.2 percentage of impairment while working
Standard Error 2.43
0.8 percentage of impairment while working
Standard Error 2.78
-7.3 percentage of impairment while working
Standard Error 5.95
-5.8 percentage of impairment while working
Standard Error 1.95
Change From Baseline in Percent Impairment While Working Due to MS on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Month 3
-8.0 percentage of impairment while working
Standard Error 2.88
-1.7 percentage of impairment while working
Standard Error 3.38
-2.9 percentage of impairment while working
Standard Error 7.57
-8.6 percentage of impairment while working
Standard Error 2.28
Change From Baseline in Percent Impairment While Working Due to MS on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Month 6
-8.7 percentage of impairment while working
Standard Error 2.79
-2.5 percentage of impairment while working
Standard Error 3.26
-8.3 percentage of impairment while working
Standard Error 6.88
-6.7 percentage of impairment while working
Standard Error 2.20
Change From Baseline in Percent Impairment While Working Due to MS on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Month 9
-1.8 percentage of impairment while working
Standard Error 3.17
0.5 percentage of impairment while working
Standard Error 3.85
-4.9 percentage of impairment while working
Standard Error 8.51
-5.0 percentage of impairment while working
Standard Error 2.49
Change From Baseline in Percent Impairment While Working Due to MS on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Month 12
1.4 percentage of impairment while working
Standard Error 3.35
6.8 percentage of impairment while working
Standard Error 3.95
-13.1 percentage of impairment while working
Standard Error 8.38
-2.9 percentage of impairment while working
Standard Error 2.56

SECONDARY outcome

Timeframe: Baseline, Months 3, 6, 9, and 12

Population: Participants in the intent-to-treat population (all participants who received at least 1 dose of study treatment and who provided at least 1 efficacy assessment at Baseline and the 3-month visit) who were included in the mixed effect model for repeated measures analysis.

WPAI-SHP is a 6-question participant-rated questionnaire to determine degree to which a specific health problem affected work productivity while at work and outside of work. Four scores are derived: percentage of absenteeism (percentage of work time missed) and presenteeism (reduced productivity while at work), overall work impairment score combining absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. Score range: 0 (not affected/no impairment) to 100 (completely affected/impaired). WPAI outcomes are expressed as impairment percentages with higher numbers indicating greater impairment and less productivity. A decrease from Baseline indicates improvement. A mixed effect model for repeated measures was used for this analysis. An unstructured covariance was used to model within-participant error. The 'overall' estimate is the average change from baseline over the whole time period (through Month 12).

Outcome measures

Outcome measures
Measure
Secondary-Progressive MS
n=52 Participants
Participants in the Responder group with secondary-progressive MS (SPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Primary-Progressive MS
n=33 Participants
Participants in the Responder group with primary-progressive MS (PPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Progressive-Relapsing MS
n=9 Participants
Participants in the Responder group with progressive-relapsing MS (PRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Relapsing-Remitting MS
n=92 Participants
Participants in the Responder group with relapsing-remitting MS (RRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Change From Baseline in Percent Overall Work Impairment Due to MS on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Overall
-6.8 percentage of overall work impairment
Standard Error 3.09
-0.8 percentage of overall work impairment
Standard Error 3.54
-6.5 percentage of overall work impairment
Standard Error 6.97
-7.5 percentage of overall work impairment
Standard Error 2.41
Change From Baseline in Percent Overall Work Impairment Due to MS on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Month 3
-10.4 percentage of overall work impairment
Standard Error 3.56
-1.7 percentage of overall work impairment
Standard Error 4.18
2.9 percentage of overall work impairment
Standard Error 9.51
-10.7 percentage of overall work impairment
Standard Error 2.74
Change From Baseline in Percent Overall Work Impairment Due to MS on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Month 6
-11.9 percentage of overall work impairment
Standard Error 3.60
-3.3 percentage of overall work impairment
Standard Error 4.22
-6.5 percentage of overall work impairment
Standard Error 8.10
-9.2 percentage of overall work impairment
Standard Error 2.81
Change From Baseline in Percent Overall Work Impairment Due to MS on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Month 9
-2.6 percentage of overall work impairment
Standard Error 4.61
1.2 percentage of overall work impairment
Standard Error 5.62
-9.7 percentage of overall work impairment
Standard Error 11.15
-4.9 percentage of overall work impairment
Standard Error 3.49
Change From Baseline in Percent Overall Work Impairment Due to MS on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Month 12
-2.1 percentage of overall work impairment
Standard Error 3.73
0.4 percentage of overall work impairment
Standard Error 4.42
-12.6 percentage of overall work impairment
Standard Error 8.31
-5.3 percentage of overall work impairment
Standard Error 2.84

SECONDARY outcome

Timeframe: Baseline, Months 3, 6, 9, and 12

Population: Participants in the intent-to-treat population (all participants who received at least 1 dose of study treatment and who provided at least 1 efficacy assessment at Baseline and the 3-month visit) who were included in the mixed effect model for repeated measures analysis.

WPAI-SHP is a 6-question participant-rated questionnaire to determine degree to which a specific health problem affected work productivity while at work and outside of work. Four scores are derived: percentage of absenteeism (percentage of work time missed) and presenteeism (reduced productivity while at work), overall work impairment score combining absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. Score range: 0 (not affected/no impairment) to 100 (completely affected/impaired). WPAI outcomes are expressed as impairment percentages with higher numbers indicating greater impairment and less productivity. A decrease from Baseline indicates improvement. A mixed effect model for repeated measures was used for this analysis. An unstructured covariance was used to model within-participant error. The 'overall' estimate is the average change from baseline over the whole time period (through Month 12).

Outcome measures

Outcome measures
Measure
Secondary-Progressive MS
n=252 Participants
Participants in the Responder group with secondary-progressive MS (SPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Primary-Progressive MS
n=116 Participants
Participants in the Responder group with primary-progressive MS (PPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Progressive-Relapsing MS
n=31 Participants
Participants in the Responder group with progressive-relapsing MS (PRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Relapsing-Remitting MS
n=251 Participants
Participants in the Responder group with relapsing-remitting MS (RRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Change From Baseline in Regular Activity Productivity Loss on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Month 3
-13.4 percentage of activity impairment
Standard Error 1.72
-8.7 percentage of activity impairment
Standard Error 2.29
-11.0 percentage of activity impairment
Standard Error 4.28
-16.2 percentage of activity impairment
Standard Error 1.74
Change From Baseline in Regular Activity Productivity Loss on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Month 9
-7.5 percentage of activity impairment
Standard Error 1.78
-7.1 percentage of activity impairment
Standard Error 2.35
-10.8 percentage of activity impairment
Standard Error 4.46
-14.9 percentage of activity impairment
Standard Error 1.79
Change From Baseline in Regular Activity Productivity Loss on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Overall
-9.8 percentage of activity impairment
Standard Error 1.47
-7.1 percentage of activity impairment
Standard Error 1.86
-12.2 percentage of activity impairment
Standard Error 3.39
-14.9 percentage of activity impairment
Standard Error 1.49
Change From Baseline in Regular Activity Productivity Loss on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Month 6
-11.1 percentage of activity impairment
Standard Error 1.76
-9.0 percentage of activity impairment
Standard Error 2.35
-14.2 percentage of activity impairment
Standard Error 4.35
-15.1 percentage of activity impairment
Standard Error 1.76
Change From Baseline in Regular Activity Productivity Loss on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by MS Disease Type: Responders
Month 12
-7.1 percentage of activity impairment
Standard Error 1.79
-3.7 percentage of activity impairment
Standard Error 2.37
-13.0 percentage of activity impairment
Standard Error 4.51
-13.5 percentage of activity impairment
Standard Error 1.79

SECONDARY outcome

Timeframe: Baseline, Months 3, 6, 9, 12

Population: Participants in the intent-to-treat population (all participants who received at least 1 dose of study treatment and who provided at least 1 efficacy assessment at Baseline and the 3-month visit) who were included in the mixed effect model for repeated measures analysis.

The SF-36 determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 primarily contribute to the PCS score of the SF-36. Items 5-8 primarily contribute to the MCS score of the SF-36. Scores on each item are summed and averaged (range: 0=worst to 100=best). Increases from baseline indicate improvement. The 'overall' estimate is the average change from baseline over the whole time period (through Month 12).

Outcome measures

Outcome measures
Measure
Secondary-Progressive MS
n=58 Participants
Participants in the Responder group with secondary-progressive MS (SPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Primary-Progressive MS
n=145 Participants
Participants in the Responder group with primary-progressive MS (PPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Progressive-Relapsing MS
n=23 Participants
Participants in the Responder group with progressive-relapsing MS (PRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Relapsing-Remitting MS
n=521 Participants
Participants in the Responder group with relapsing-remitting MS (RRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Change From Baseline in the PCS of the SF-36 at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Month 3
0.1 units on a scale
Standard Error 0.77
4.1 units on a scale
Standard Error 0.53
-1.2 units on a scale
Standard Error 1.19
4.0 units on a scale
Standard Error 0.38
Change From Baseline in the PCS of the SF-36 at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Month 6
0.6 units on a scale
Standard Error 0.89
3.9 units on a scale
Standard Error 0.58
-0.8 units on a scale
Standard Error 1.35
3.1 units on a scale
Standard Error 0.40
Change From Baseline in the PCS of the SF-36 at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Month 9
-1.2 units on a scale
Standard Error 0.91
4.0 units on a scale
Standard Error 0.58
-0.7 units on a scale
Standard Error 1.46
2.7 units on a scale
Standard Error 0.40
Change From Baseline in the PCS of the SF-36 at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Month 12
-0.8 units on a scale
Standard Error 0.94
3.6 units on a scale
Standard Error 0.58
0.2 units on a scale
Standard Error 1.44
2.5 units on a scale
Standard Error 0.40
Change From Baseline in the PCS of the SF-36 at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Overall
-0.3 units on a scale
Standard Error 0.71
3.9 units on a scale
Standard Error 0.48
-0.6 units on a scale
Standard Error 1.08
3.1 units on a scale
Standard Error 0.36

SECONDARY outcome

Timeframe: Baseline, Months 3, 6, 9, 12

Population: Participants in the intent-to-treat population (all participants who received at least 1 dose of study treatment and who provided at least 1 efficacy assessment at Baseline and the 3-month visit) who were included in the mixed effect model for repeated measures analysis.

The SF-36 determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 primarily contribute to the PCS score of the SF-36. Items 5-8 primarily contribute to the MCS score of the SF-36. Scores on each item are summed and averaged (range: 0=worst to 100=best). Increases from baseline indicate improvement. The 'overall' estimate is the average change from baseline over the whole time period (through Month 12).

Outcome measures

Outcome measures
Measure
Secondary-Progressive MS
n=58 Participants
Participants in the Responder group with secondary-progressive MS (SPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Primary-Progressive MS
n=145 Participants
Participants in the Responder group with primary-progressive MS (PPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Progressive-Relapsing MS
n=23 Participants
Participants in the Responder group with progressive-relapsing MS (PRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Relapsing-Remitting MS
n=522 Participants
Participants in the Responder group with relapsing-remitting MS (RRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Change From Baseline in the MCS of the SF-36 at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Overall
-0.1 units on a scale
Standard Error 1.09
3.9 units on a scale
Standard Error 0.74
0.6 units on a scale
Standard Error 1.64
2.8 units on a scale
Standard Error 0.56
Change From Baseline in the MCS of the SF-36 at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Month 3
-1.3 units on a scale
Standard Error 1.18
4.8 units on a scale
Standard Error 0.81
1.1 units on a scale
Standard Error 1.82
4.0 units on a scale
Standard Error 0.59
Change From Baseline in the MCS of the SF-36 at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Month 6
0.2 units on a scale
Standard Error 1.29
4.1 units on a scale
Standard Error 0.85
1.5 units on a scale
Standard Error 1.96
3.0 units on a scale
Standard Error 0.60
Change From Baseline in the MCS of the SF-36 at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Month 9
1.3 units on a scale
Standard Error 1.40
2.8 units on a scale
Standard Error 0.89
0.0 units on a scale
Standard Error 2.24
2.1 units on a scale
Standard Error 0.62
Change From Baseline in the MCS of the SF-36 at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Month 12
-0.7 units on a scale
Standard Error 1.40
3.9 units on a scale
Standard Error 0.87
-0.3 units on a scale
Standard Error 2.15
2.1 units on a scale
Standard Error 0.61

SECONDARY outcome

Timeframe: Baseline, Months 3, 6, 9, and 12

Population: Participants in the intent-to-treat population (all participants who received at least 1 dose of study treatment and who provided at least 1 efficacy assessment at Baseline and the 3-month visit) who were included in the mixed effect model for repeated measures analysis.

The MSIS-29 is a disease specific patient-reported outcome measure that has been developed and validated to examine the physical and psychological impact of MS from a patient's perspective; it measures 20 physical items and 9 psychological items. Sum of 20 physical condition items converted into a 0-100 score range, where missing items are imputed by average of total of non-missing items when no more than 50% are missing (otherwise the total score is missing). A lower total score indicates less physically-related impact while a higher total score indicates greater physically-related impact on a participant's functioning. Decreases from Baseline indicate improvement. A mixed effect model for repeated measures was used for this analysis. An unstructured covariance was used to model within-participant error. The 'overall' estimate is the average change from baseline over the whole time period (through Month 12).

Outcome measures

Outcome measures
Measure
Secondary-Progressive MS
n=57 Participants
Participants in the Responder group with secondary-progressive MS (SPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Primary-Progressive MS
n=145 Participants
Participants in the Responder group with primary-progressive MS (PPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Progressive-Relapsing MS
n=22 Participants
Participants in the Responder group with progressive-relapsing MS (PRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Relapsing-Remitting MS
n=524 Participants
Participants in the Responder group with relapsing-remitting MS (RRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Change From Baseline in the MSIS-29 Physical Score at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Overall
-1.5 units on a scale
Standard Error 2.03
-12.2 units on a scale
Standard Error 1.38
-3.2 units on a scale
Standard Error 3.10
-9.6 units on a scale
Standard Error 1.05
Change From Baseline in the MSIS-29 Physical Score at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Month 3
-1.4 units on a scale
Standard Error 2.08
-14.0 units on a scale
Standard Error 1.43
-4.0 units on a scale
Standard Error 3.22
-12.6 units on a scale
Standard Error 1.07
Change From Baseline in the MSIS-29 Physical Score at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Month 6
-2.2 units on a scale
Standard Error 2.28
-12.2 units on a scale
Standard Error 1.52
-5.2 units on a scale
Standard Error 3.47
-10.0 units on a scale
Standard Error 1.10
Change From Baseline in the MSIS-29 Physical Score at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Month 9
-0.4 units on a scale
Standard Error 2.48
-11.8 units on a scale
Standard Error 1.61
0.5 units on a scale
Standard Error 4.02
-8.0 units on a scale
Standard Error 1.13
Change From Baseline in the MSIS-29 Physical Score at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Month 12
-2.1 units on a scale
Standard Error 2.57
-11.1 units on a scale
Standard Error 1.61
-4.3 units on a scale
Standard Error 3.95
-7.8 units on a scale
Standard Error 1.13

SECONDARY outcome

Timeframe: Months 3, 6, 9, and 12

Population: Participants in the intent-to-treat population (all participants who received at least 1 dose of study treatment and who provided at least 1 efficacy assessment at Baseline and the 3-month visit) who were included in the mixed effect model for repeated measures analysis.

The MSIS-29 is a disease-specific patient-reported outcome measure that has been developed and validated to examine the physical and psychological impact of MS from a patient's perspective; it measures 20 physical items and 9 psychological items. Sum of 9 psychological condition items converted into a 0-100 score range, where missing items are imputed by average of total of non-missing items when no more than 50% are missing (otherwise the total score is missing). A lower total score indicates less psychologically-related impact while a higher total score indicates greater psychologically-related impact on a participant's functioning. Decreases from Baseline indicate improvement. A mixed effect model for repeated measures was used for this analysis. An unstructured covariance was used to model within-participant error. The 'overall' estimate is the average change from baseline over the whole time period (through Month 12).

Outcome measures

Outcome measures
Measure
Secondary-Progressive MS
n=57 Participants
Participants in the Responder group with secondary-progressive MS (SPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Primary-Progressive MS
n=144 Participants
Participants in the Responder group with primary-progressive MS (PPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Progressive-Relapsing MS
n=22 Participants
Participants in the Responder group with progressive-relapsing MS (PRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Relapsing-Remitting MS
n=525 Participants
Participants in the Responder group with relapsing-remitting MS (RRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Change From Baseline in MSIS-29 Psychological Score at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Month 6
-2.6 units on a scale
Standard Error 2.37
-9.5 units on a scale
Standard Error 1.56
-2.6 units on a scale
Standard Error 3.60
-7.1 units on a scale
Standard Error 1.10
Change From Baseline in MSIS-29 Psychological Score at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Month 9
-0.2 units on a scale
Standard Error 2.57
-8.9 units on a scale
Standard Error 1.64
-2.4 units on a scale
Standard Error 4.22
-6.1 units on a scale
Standard Error 1.13
Change From Baseline in MSIS-29 Psychological Score at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Month 12
1.3 units on a scale
Standard Error 2.70
-9.1 units on a scale
Standard Error 1.67
-5.1 units on a scale
Standard Error 4.16
-6.2 units on a scale
Standard Error 1.13
Change From Baseline in MSIS-29 Psychological Score at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Overall
-0.3 units on a scale
Standard Error 2.00
-9.7 units on a scale
Standard Error 1.36
-2.8 units on a scale
Standard Error 3.06
-7.1 units on a scale
Standard Error 1.02
Change From Baseline in MSIS-29 Psychological Score at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Month 3
0.2 units on a scale
Standard Error 2.17
-11.1 units on a scale
Standard Error 1.49
-1.0 units on a scale
Standard Error 3.39
-9.0 units on a scale
Standard Error 1.07

SECONDARY outcome

Timeframe: Baseline, Months 3, 6, 9, 12

Population: Participants in the intent-to-treat population (all participants who received at least 1 dose of study treatment and who provided at least 1 efficacy assessment at Baseline and the 3-month visit) who were included in the mixed effect model for repeated measures analysis.

The PRIMUS activity measure is a 15-item assessment of patient-reported activities of daily living. The total score was calculated as sum of all 15 items converted into a 0-30 range, where missing items were imputed by average of non-missing total when no more than 50% of items were missing (otherwise, the total score is missing). Higher score indicates worse condition. A decrease from Baseline indicates improvement. A mixed effect model for repeated measures was used for this analysis. An unstructured covariance was used to model within-participant error. The 'overall' estimate is the average change from baseline over the whole time period (through Month 12).

Outcome measures

Outcome measures
Measure
Secondary-Progressive MS
n=33 Participants
Participants in the Responder group with secondary-progressive MS (SPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Primary-Progressive MS
n=103 Participants
Participants in the Responder group with primary-progressive MS (PPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Progressive-Relapsing MS
n=12 Participants
Participants in the Responder group with progressive-relapsing MS (PRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Relapsing-Remitting MS
n=395 Participants
Participants in the Responder group with relapsing-remitting MS (RRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Change From Baseline in the Activities Limitation Scale of the PRIMUS at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Overall
0.8 units on a scale
Standard Error 0.63
-1.9 units on a scale
Standard Error 0.37
0.8 units on a scale
Standard Error 1.11
-1.3 units on a scale
Standard Error 0.24
Change From Baseline in the Activities Limitation Scale of the PRIMUS at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Month 3
-0.5 units on a scale
Standard Error 0.67
-2.9 units on a scale
Standard Error 0.40
-0.0 units on a scale
Standard Error 1.14
-2.1 units on a scale
Standard Error 0.25
Change From Baseline in the Activities Limitation Scale of the PRIMUS at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Month 6
0.6 units on a scale
Standard Error 0.81
-2.1 units on a scale
Standard Error 0.46
1.3 units on a scale
Standard Error 1.33
-1.2 units on a scale
Standard Error 0.27
Change From Baseline in the Activities Limitation Scale of the PRIMUS at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Month 9
2.0 units on a scale
Standard Error 0.82
-1.6 units on a scale
Standard Error 0.46
1.1 units on a scale
Standard Error 1.67
-1.1 units on a scale
Standard Error 0.27
Change From Baseline in the Activities Limitation Scale of the PRIMUS at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Month 12
1.1 units on a scale
Standard Error 0.93
-1.0 units on a scale
Standard Error 0.50
1.0 units on a scale
Standard Error 1.81
-0.7 units on a scale
Standard Error 0.29

SECONDARY outcome

Timeframe: Baseline, Months 3, 6, 9, 12

Population: Participants in the intent-to-treat population (all participants who received at least 1 dose of study treatment and who provided at least 1 efficacy assessment at Baseline and the 3-month visit) who were included in the mixed effect model for repeated measures analysis.

EQ-5D is a participant-answered questionnaire containing a descriptive system of 5 dimensions - mobility, self-care, usual activities, pain/discomfort and anxiety/depression and a VAS on health state. The EQ-5D VAS ranges from 0 (worst health state) to 100 (best health state). An increase from baseline indicates improvement. A mixed effect model for repeated measures was used for this analysis. An unstructured covariance was used to model within-participant error. The 'overall' estimate is the average change from baseline over the whole time period (through Month 12).

Outcome measures

Outcome measures
Measure
Secondary-Progressive MS
n=58 Participants
Participants in the Responder group with secondary-progressive MS (SPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Primary-Progressive MS
n=141 Participants
Participants in the Responder group with primary-progressive MS (PPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Progressive-Relapsing MS
n=21 Participants
Participants in the Responder group with progressive-relapsing MS (PRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Relapsing-Remitting MS
n=518 Participants
Participants in the Responder group with relapsing-remitting MS (RRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Change From Baseline in the Current Health State of EQ-5D VAS at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Month 9
-6.1 units on a scale
Standard Error 2.51
8.7 units on a scale
Standard Error 1.62
-1.8 units on a scale
Standard Error 4.13
5.5 units on a scale
Standard Error 1.11
Change From Baseline in the Current Health State of EQ-5D VAS at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Month 12
-7.7 units on a scale
Standard Error 2.67
8.7 units on a scale
Standard Error 1.67
-1.5 units on a scale
Standard Error 4.33
5.5 units on a scale
Standard Error 1.12
Change From Baseline in the Current Health State of EQ-5D VAS at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Overall
-5.8 units on a scale
Standard Error 1.95
8.6 units on a scale
Standard Error 1.33
-0.8 units on a scale
Standard Error 3.04
6.0 units on a scale
Standard Error 1.00
Change From Baseline in the Current Health State of EQ-5D VAS at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Month 3
-3.9 units on a scale
Standard Error 2.16
8.6 units on a scale
Standard Error 1.49
-1.2 units on a scale
Standard Error 3.46
7.6 units on a scale
Standard Error 1.06
Change From Baseline in the Current Health State of EQ-5D VAS at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Month 6
-5.6 units on a scale
Standard Error 2.35
8.6 units on a scale
Standard Error 1.56
1.5 units on a scale
Standard Error 3.72
5.2 units on a scale
Standard Error 1.09

SECONDARY outcome

Timeframe: Baseline, Months 3, 6, 9, 12

Population: Participants in the intent-to-treat population (all participants who received at least 1 dose of study treatment and who provided at least 1 efficacy assessment at Baseline and the 3-month visit) who were included in the mixed effect model for repeated measures analysis.

EQ-5D is a participant-answered questionnaire containing a descriptive system on 5 dimensions - mobility, self-care, usual activities, pain/discomfort and anxiety/depression and a VAS on health state. The scores on the 5 dimensions of descriptive system can be converted into an index score by applying UK weights. EQ-5D index score ranges from 1 to -0.59, and 1 reflects the best outcome. An increase from baseline indicates improvement. A mixed effect model for repeated measures was used for this analysis. An unstructured covariance was used to model within-participant error. The 'overall' estimate is the average change from baseline over the whole time period (through Month 12).

Outcome measures

Outcome measures
Measure
Secondary-Progressive MS
n=56 Participants
Participants in the Responder group with secondary-progressive MS (SPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Primary-Progressive MS
n=142 Participants
Participants in the Responder group with primary-progressive MS (PPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Progressive-Relapsing MS
n=22 Participants
Participants in the Responder group with progressive-relapsing MS (PRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Relapsing-Remitting MS
n=519 Participants
Participants in the Responder group with relapsing-remitting MS (RRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Change From Baseline in the Index Scores of EQ-5D at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Overall
-0.00 units on a scale
Standard Error 0.02
0.06 units on a scale
Standard Error 0.02
0.02 units on a scale
Standard Error 0.03
0.04 units on a scale
Standard Error 0.01
Change From Baseline in the Index Scores of EQ-5D at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Month 3
0.02 units on a scale
Standard Error 0.02
0.07 units on a scale
Standard Error 0.02
-0.02 units on a scale
Standard Error 0.04
0.07 units on a scale
Standard Error 0.01
Change From Baseline in the Index Scores of EQ-5D at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Month 6
-0.00 units on a scale
Standard Error 0.03
0.05 units on a scale
Standard Error 0.02
0.03 units on a scale
Standard Error 0.04
0.05 units on a scale
Standard Error 0.01
Change From Baseline in the Index Scores of EQ-5D at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Month 9
-0.00 units on a scale
Standard Error 0.03
0.06 units on a scale
Standard Error 0.02
0.02 units on a scale
Standard Error 0.05
0.03 units on a scale
Standard Error 0.01
Change From Baseline in the Index Scores of EQ-5D at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Month 12
-0.03 units on a scale
Standard Error 0.03
0.07 units on a scale
Standard Error 0.02
0.04 units on a scale
Standard Error 0.05
0.03 units on a scale
Standard Error 0.01

SECONDARY outcome

Timeframe: Baseline, Months 3, 6, 9, and 12

Population: Participants in the intent-to-treat population (all participants who received at least 1 dose of study treatment and who provided at least 1 efficacy assessment at Baseline and the 3-month visit) who were included in the mixed effect model for repeated measures analysis.

WPAI-SHP is a 6-question participant-rated questionnaire to determine degree to which a specific health problem affected work productivity while at work and outside of work. Four scores are derived: percentage of absenteeism (percentage of work time missed) and presenteeism (reduced productivity while at work), overall work impairment score combining absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. Score range: 0 (not affected/no impairment) to 100 (completely affected/impaired). WPAI outcomes are expressed as impairment percentages with higher numbers indicating greater impairment and less productivity. A decrease from Baseline indicates improvement. A mixed effect model for repeated measures was used for this analysis. An unstructured covariance was used to model within-participant error. The 'overall' estimate is the average change from baseline over the whole time period (through Month 12).

Outcome measures

Outcome measures
Measure
Secondary-Progressive MS
n=12 Participants
Participants in the Responder group with secondary-progressive MS (SPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Primary-Progressive MS
n=42 Participants
Participants in the Responder group with primary-progressive MS (PPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Progressive-Relapsing MS
n=2 Participants
Participants in the Responder group with progressive-relapsing MS (PRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Relapsing-Remitting MS
n=149 Participants
Participants in the Responder group with relapsing-remitting MS (RRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Change From Baseline in Percent Work Time Missed Due to MS on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Overall
-11.9 percentage of work time missed
Standard Error 4.93
-2.4 percentage of work time missed
Standard Error 2.72
14.9 percentage of work time missed
Standard Error 12.11
-3.0 percentage of work time missed
Standard Error 2.10
Change From Baseline in Percent Work Time Missed Due to MS on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Month 6
-10.3 percentage of work time missed
Standard Error 5.52
-4.3 percentage of work time missed
Standard Error 2.98
6.4 percentage of work time missed
Standard Error 12.11
-6.0 percentage of work time missed
Standard Error 2.21
Change From Baseline in Percent Work Time Missed Due to MS on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Month 9
-12.8 percentage of work time missed
Standard Error 8.32
-2.1 percentage of work time missed
Standard Error 4.09
13.9 percentage of work time missed
Standard Error 21.98
-1.2 percentage of work time missed
Standard Error 2.60
Change From Baseline in Percent Work Time Missed Due to MS on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Month 12
-16.2 percentage of work time missed
Standard Error 7.16
-1.1 percentage of work time missed
Standard Error 3.79
10.6 percentage of work time missed
Standard Error 15.59
-1.0 percentage of work time missed
Standard Error 2.53
Change From Baseline in Percent Work Time Missed Due to MS on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Month 3
-8.3 percentage of work time missed
Standard Error 6.14
-2.0 percentage of work time missed
Standard Error 3.43
28.6 percentage of work time missed
Standard Error 17.71
-3.7 percentage of work time missed
Standard Error 2.43

SECONDARY outcome

Timeframe: Baseline, Months 3, 6, 9, and 12

Population: Participants in the intent-to-treat population (all participants who received at least 1 dose of study treatment and who provided at least 1 efficacy assessment at Baseline and the 3-month visit) who were included in the mixed effect model for repeated measures analysis.

WPAI-SHP is a 6-question participant-rated questionnaire to determine degree to which a specific health problem affected work productivity while at work and outside of work. Four scores are derived: percentage of absenteeism (percentage of work time missed) and presenteeism (reduced productivity while at work), overall work impairment score combining absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. Score range: 0 (not affected/no impairment) to 100 (completely affected/impaired). WPAI outcomes are expressed as impairment percentages with higher numbers indicating greater impairment and less productivity. A decrease from Baseline indicates improvement. A mixed effect model for repeated measures was used for this analysis. An unstructured covariance was used to model within-participant error. The 'overall' estimate is the average change from baseline over the whole time period (through Month 12).

Outcome measures

Outcome measures
Measure
Secondary-Progressive MS
n=13 Participants
Participants in the Responder group with secondary-progressive MS (SPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Primary-Progressive MS
n=49 Participants
Participants in the Responder group with primary-progressive MS (PPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Progressive-Relapsing MS
n=3 Participants
Participants in the Responder group with progressive-relapsing MS (PRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Relapsing-Remitting MS
n=168 Participants
Participants in the Responder group with relapsing-remitting MS (RRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Change From Baseline in Percent Impairment While Working Due to MS on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Overall
-7.3 percentage of impairment while working
Standard Error 5.00
-6.4 percentage of impairment while working
Standard Error 2.69
-11.5 percentage of impairment while working
Standard Error 10.86
-3.1 percentage of impairment while working
Standard Error 2.10
Change From Baseline in Percent Impairment While Working Due to MS on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Month 9
-19.0 percentage of impairment while working
Standard Error 7.31
-5.6 percentage of impairment while working
Standard Error 3.55
-6.0 percentage of impairment while working
Standard Error 18.93
-1.9 percentage of impairment while working
Standard Error 2.44
Change From Baseline in Percent Impairment While Working Due to MS on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Month 3
-1.0 percentage of impairment while working
Standard Error 6.02
-8.1 percentage of impairment while working
Standard Error 3.24
-3.3 percentage of impairment while working
Standard Error 14.07
-6.1 percentage of impairment while working
Standard Error 2.35
Change From Baseline in Percent Impairment While Working Due to MS on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Month 6
-3.8 percentage of impairment while working
Standard Error 5.89
-8.0 percentage of impairment while working
Standard Error 3.06
-15.9 percentage of impairment while working
Standard Error 13.27
-5.6 percentage of impairment while working
Standard Error 2.26
Change From Baseline in Percent Impairment While Working Due to MS on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Month 12
-5.5 percentage of impairment while working
Standard Error 7.56
-3.8 percentage of impairment while working
Standard Error 3.65
-20.7 percentage of impairment while working
Standard Error 15.27
1.1 percentage of impairment while working
Standard Error 2.49

SECONDARY outcome

Timeframe: Baseline, Months 3, 6, 9, and 12

Population: Participants in the intent-to-treat population (all participants who received at least 1 dose of study treatment and who provided at least 1 efficacy assessment at Baseline and the 3-month visit) who were included in the mixed effect model for repeated measures analysis.

WPAI-SHP is a 6-question participant-rated questionnaire to determine degree to which a specific health problem affected work productivity while at work and outside of work. Four scores are derived: percentage of absenteeism (percentage of work time missed) and presenteeism (reduced productivity while at work), overall work impairment score combining absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. Score range: 0 (not affected/no impairment) to 100 (completely affected/impaired). WPAI outcomes are expressed as impairment percentages with higher numbers indicating greater impairment and less productivity. A decrease from Baseline indicates improvement. A mixed effect model for repeated measures was used for this analysis. An unstructured covariance was used to model within-participant error. The 'overall' estimate is the average change from baseline over the whole time period (through Month 12).

Outcome measures

Outcome measures
Measure
Secondary-Progressive MS
n=11 Participants
Participants in the Responder group with secondary-progressive MS (SPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Primary-Progressive MS
n=41 Participants
Participants in the Responder group with primary-progressive MS (PPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Progressive-Relapsing MS
n=2 Participants
Participants in the Responder group with progressive-relapsing MS (PRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Relapsing-Remitting MS
n=145 Participants
Participants in the Responder group with relapsing-remitting MS (RRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Change From Baseline in Percent Overall Work Impairment Due to MS on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Month 3
-6.6 percentage of overall work impairment
Standard Error 6.99
-7.1 percentage of overall work impairment
Standard Error 3.85
18.0 percentage of overall work impairment
Standard Error 21.17
-7.9 percentage of overall work impairment
Standard Error 2.84
Change From Baseline in Percent Overall Work Impairment Due to MS on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Month 6
-1.8 percentage of overall work impairment
Standard Error 7.48
-7.7 percentage of overall work impairment
Standard Error 3.85
-8.2 percentage of overall work impairment
Standard Error 15.87
-7.8 percentage of overall work impairment
Standard Error 2.78
Change From Baseline in Percent Overall Work Impairment Due to MS on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Month 9
-18.5 percentage of overall work impairment
Standard Error 10.69
-5.5 percentage of overall work impairment
Standard Error 5.15
3.7 percentage of overall work impairment
Standard Error 25.71
-1.6 percentage of overall work impairment
Standard Error 3.22
Change From Baseline in Percent Overall Work Impairment Due to MS on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Overall
-9.9 percentage of overall work impairment
Standard Error 6.26
-6.7 percentage of overall work impairment
Standard Error 3.32
1.2 percentage of overall work impairment
Standard Error 14.53
-4.8 percentage of overall work impairment
Standard Error 2.55
Change From Baseline in Percent Overall Work Impairment Due to MS on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Month 12
-12.6 percentage of overall work impairment
Standard Error 7.95
-6.5 percentage of overall work impairment
Standard Error 4.02
-8.6 percentage of overall work impairment
Standard Error 15.29
-1.8 percentage of overall work impairment
Standard Error 2.81

SECONDARY outcome

Timeframe: Baseline, Months 3, 6, 9, and 12

Population: Participants in the intent-to-treat population (all participants who received at least 1 dose of study treatment and who provided at least 1 efficacy assessment at Baseline and the 3-month visit) who were included in the mixed effect model for repeated measures analysis.

WPAI-SHP is a 6-question participant-rated questionnaire to determine degree to which a specific health problem affected work productivity while at work and outside of work. Four scores are derived: percentage of absenteeism (percentage of work time missed) and presenteeism (reduced productivity while at work), overall work impairment score combining absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. Score range: 0 (not affected/no impairment) to 100 (completely affected/impaired). WPAI outcomes are expressed as impairment percentages with higher numbers indicating greater impairment and less productivity. A decrease from Baseline indicates improvement. A mixed effect model for repeated measures was used for this analysis. An unstructured covariance was used to model within-participant error. The 'overall' estimate is the average change from baseline over the whole time period (through Month 12).

Outcome measures

Outcome measures
Measure
Secondary-Progressive MS
n=56 Participants
Participants in the Responder group with secondary-progressive MS (SPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Primary-Progressive MS
n=141 Participants
Participants in the Responder group with primary-progressive MS (PPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Progressive-Relapsing MS
n=21 Participants
Participants in the Responder group with progressive-relapsing MS (PRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Relapsing-Remitting MS
n=509 Participants
Participants in the Responder group with relapsing-remitting MS (RRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Change From Baseline in Regular Activity Productivity Loss on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Overall
-4.2 percentage of activity impairment
Standard Error 2.69
-13.3 percentage of activity impairment
Standard Error 1.83
-3.1 percentage of activity impairment
Standard Error 4.15
-10.6 percentage of activity impairment
Standard Error 1.39
Change From Baseline in Regular Activity Productivity Loss on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Month 3
-3.4 percentage of activity impairment
Standard Error 3.24
-15.7 percentage of activity impairment
Standard Error 2.20
-1.8 percentage of activity impairment
Standard Error 5.15
-12.7 percentage of activity impairment
Standard Error 1.53
Change From Baseline in Regular Activity Productivity Loss on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Month 6
-6.3 percentage of activity impairment
Standard Error 3.40
-14.6 percentage of activity impairment
Standard Error 2.23
-0.5 percentage of activity impairment
Standard Error 5.20
-11.5 percentage of activity impairment
Standard Error 1.54
Change From Baseline in Regular Activity Productivity Loss on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Month 9
-5.9 percentage of activity impairment
Standard Error 3.50
-12.0 percentage of activity impairment
Standard Error 2.28
1.6 percentage of activity impairment
Standard Error 5.86
-9.8 percentage of activity impairment
Standard Error 1.55
Change From Baseline in Regular Activity Productivity Loss on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy
Month 12
-1.3 percentage of activity impairment
Standard Error 3.70
-10.9 percentage of activity impairment
Standard Error 2.31
-11.6 percentage of activity impairment
Standard Error 5.72
-8.5 percentage of activity impairment
Standard Error 1.56

SECONDARY outcome

Timeframe: From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose)

Population: Intent-to-treat population: all participants who received at least 1 dose of study treatment and who provided at least 1 efficacy assessment at Baseline and the 3-month visit.

AE: any untoward medical occurrence that did not necessarily have a causal relationship with study treatment. SAE: any untoward medical occurrence that at any dose: resulted in death; in the view of the Investigator, placed the subject at immediate risk of death (a life threatening event); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in a congenital anomaly/birth defect; any other medically important event that, in the opinion of the Investigator, could have jeopardized the subject or may have required intervention to prevent one of the other outcomes listed in the definition above.

Outcome measures

Outcome measures
Measure
Secondary-Progressive MS
n=128 Participants
Participants in the Responder group with secondary-progressive MS (SPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Primary-Progressive MS
n=835 Participants
Participants in the Responder group with primary-progressive MS (PPMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Progressive-Relapsing MS
Participants in the Responder group with progressive-relapsing MS (PRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Relapsing-Remitting MS
n=707 Participants
Participants in the Responder group with relapsing-remitting MS (RRMS). Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs)
Severe AE
2 participants
50 participants
48 participants
Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs)
Study treatment related AE
37 participants
285 participants
248 participants
Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs)
Study treatment related SAE
0 participants
7 participants
7 participants
Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs)
Death
0 participants
2 participants
2 participants
Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs)
AE leading to study drug discontinuation
8 participants
40 participants
32 participants
Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs)
AE leading to study discontinuation
1 participants
19 participants
18 participants
Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs)
AE
64 participants
586 participants
522 participants
Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs)
SAE
3 participants
79 participants
76 participants

Adverse Events

Responder

Serious events: 76 serious events
Other events: 314 other events
Deaths: 0 deaths

Non-responder

Serious events: 3 serious events
Other events: 41 other events
Deaths: 0 deaths

All Participants

Serious events: 79 serious events
Other events: 355 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Responder
n=707 participants at risk
Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Non-responder
n=128 participants at risk
Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment non-responders continued without treatment by completing quality of life questionnaires.
All Participants
n=835 participants at risk
All participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks. Those deemed treatment non-responders continued without treatment by completing quality of life questionnaires.
Nervous system disorders
Multiple Sclerosis Relapse
2.7%
19/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
2.3%
19/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Nervous system disorders
Grand Mal Convulsion
0.28%
2/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.24%
2/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Nervous system disorders
Multiple Sclerosis
0.28%
2/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.24%
2/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Nervous system disorders
Cerebral Venous Thrombosis
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Nervous system disorders
Cerebrovascular Accident
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Nervous system disorders
Convulsion
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Nervous system disorders
Dyskinesia
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Nervous system disorders
Epilepsy
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Nervous system disorders
Muscle Spasticity
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Nervous system disorders
Paraesthesia
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Nervous system disorders
Paraparesis
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Nervous system disorders
Progressive Multiple Sclerosis
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Nervous system disorders
Syncope
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Nervous system disorders
Trigeminal Neuralgia
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Nervous system disorders
Uhthoff's Phenomenon
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Injury, poisoning and procedural complications
Fall
1.3%
9/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
1.1%
9/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Injury, poisoning and procedural complications
Upper Limb Fracture
0.28%
2/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.24%
2/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Injury, poisoning and procedural complications
Avulsion Fracture
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Injury, poisoning and procedural complications
Fibula Fracture
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Injury, poisoning and procedural complications
Hand Fracture
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Injury, poisoning and procedural complications
Hip Fracture
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Injury, poisoning and procedural complications
Joint Injury
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Injury, poisoning and procedural complications
Lower Limb Fracture
0.00%
0/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.78%
1/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Injury, poisoning and procedural complications
Traumatic Intracranial Haemorrhage
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Injury, poisoning and procedural complications
Wound
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Injury, poisoning and procedural complications
Wrist Fracture
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Infections and infestations
Urinary Tract Infection
0.42%
3/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.78%
1/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.48%
4/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Infections and infestations
Appendicitis
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Infections and infestations
Chronic Sinusitis
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Infections and infestations
Gastrointestinal Viral Infection
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Infections and infestations
Peritonitis
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Infections and infestations
Pneumonia Influenzal
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Infections and infestations
Urosepsis
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Infections and infestations
Viral Infection
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Musculoskeletal and connective tissue disorders
Bursitis
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Musculoskeletal and connective tissue disorders
Cervical Spinal Stenosis
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Musculoskeletal and connective tissue disorders
Exostosis
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Musculoskeletal and connective tissue disorders
Foot Deformity
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Musculoskeletal and connective tissue disorders
Musculoskeletal Pain
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Musculoskeletal and connective tissue disorders
Musculoskeletal Stiffness
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Musculoskeletal and connective tissue disorders
Rotator Cuff Syndrome
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Musculoskeletal and connective tissue disorders
Synovial Cyst
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Musculoskeletal and connective tissue disorders
Vertebral Foraminal Stenosis
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Cardiac disorders
Arrhythmia
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Cardiac disorders
Atrial Fibrillation
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Cardiac disorders
Cardiovascular Disorder
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Cardiac disorders
Myocardial Infarction
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Reproductive system and breast disorders
Benign Prostatic Hyperplasia
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Reproductive system and breast disorders
Erectile Dysfunction
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Reproductive system and breast disorders
Metrorrhagia
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Reproductive system and breast disorders
Ovarian Cyst Ruptured
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Blood and lymphatic system disorders
Anaemia
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Blood and lymphatic system disorders
Microcytic Anaemia
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant Melanoma Stage IV
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Uterine Leiomyoma
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Psychiatric disorders
Hypomania
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Psychiatric disorders
Suicide Attempt
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Renal and urinary disorders
Bladder Disorder
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Renal and urinary disorders
Bladder Dysfunction
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Surgical and medical procedures
Liposuction
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Surgical and medical procedures
Stent Placement
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Surgical and medical procedures
Stent Removal
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Gastrointestinal disorders
Colitis
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
General disorders
Death
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Hepatobiliary disorders
Cholecystitis Acute
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Metabolism and nutrition disorders
Fluid Retention
0.00%
0/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.78%
1/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Respiratory, thoracic and mediastinal disorders
Lung Disorder
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Skin and subcutaneous tissue disorders
Decubitus Ulcer
0.14%
1/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.00%
0/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.12%
1/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).

Other adverse events

Other adverse events
Measure
Responder
n=707 participants at risk
Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks.
Non-responder
n=128 participants at risk
Participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment non-responders continued without treatment by completing quality of life questionnaires.
All Participants
n=835 participants at risk
All participants took 10 mg fampridine twice daily for the first 4 weeks. Those deemed treatment responders continued 10 mg fampridine twice daily for 44 weeks. Those deemed treatment non-responders continued without treatment by completing quality of life questionnaires.
Nervous system disorders
Headache
10.5%
74/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
4.7%
6/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
9.6%
80/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Nervous system disorders
Multiple Sclerosis Relapse
8.9%
63/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
1.6%
2/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
7.8%
65/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Nervous system disorders
Dizziness
5.0%
35/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
6.2%
8/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
5.1%
43/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Infections and infestations
Urinary Tract Infection
8.2%
58/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
5.5%
7/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
7.8%
65/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Infections and infestations
Nasopharyngitis
8.5%
60/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
0.78%
1/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
7.3%
61/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Gastrointestinal disorders
Nausea
8.5%
60/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
4.7%
6/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
7.9%
66/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Psychiatric disorders
Insomnia
11.7%
83/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
9.4%
12/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
11.4%
95/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
General disorders
Fatigue
4.4%
31/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
5.5%
7/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
4.6%
38/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
Injury, poisoning and procedural complications
Fall
7.1%
50/707 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
3.9%
5/128 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).
6.6%
55/835 • From signing of Informed Consent (SAEs) or from first dose of study treatment (AEs) through Week 50 or Early Termination (14 +/- 7 days after last dose).

Additional Information

Biogen Study Medical Director

Biogen

Results disclosure agreements

  • Principal investigator is a sponsor employee Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.
  • Publication restrictions are in place

Restriction type: OTHER